Initiation and outcomes of women pursuing planned fertility preservation.

Autor:	Boedeker D; Department of Gynecologic Surgery and Obstetrics, Walter Reed National Military Medical Center, Bethesda, Maryland., Brolinson M; Eunice Kennedy Shriver National Institute of Child Health and Human Development, Reproductive Endocrinology and Infertility Fellowship Program, National Institutes of Health, Bethesda, Maryland., Campedelli AC; Department of Gynecologic Surgery and Obstetrics, Uniformed Services University of Health Sciences, Bethesda, Maryland., Yu R; Department of Gynecologic Surgery and Obstetrics, Uniformed Services University of Health Sciences, Bethesda, Maryland., Raiciulescu S; Department of Preventive Medicine and Biostatistics, Uniformed Services University of Health Sciences, Bethesda, Maryland., Devine K; Shady Grove Fertility Center, Rockville, Maryland., Hill M; Department of Gynecologic Surgery and Obstetrics, Walter Reed National Military Medical Center, Bethesda, Maryland; Eunice Kennedy Shriver National Institute of Child Health and Human Development, Reproductive Endocrinology and Infertility Fellowship Program, National Institutes of Health, Bethesda, Maryland., DeCherney A; Eunice Kennedy Shriver National Institute of Child Health and Human Development, Reproductive Endocrinology and Infertility Fellowship Program, National Institutes of Health, Bethesda, Maryland., Spitzer T; Department of Gynecologic Surgery and Obstetrics, Uniformed Services University of Health Sciences, Bethesda, Maryland. Electronic address: trimble.spitzer@usuhs.edu.
Jazyk:	angličtina
Zdroj:	Fertility and sterility [Fertil Steril] 2025 Jan; Vol. 123 (1), pp. 148-155. Date of Electronic Publication: 2024 Aug 08.
DOI:	10.1016/j.fertnstert.2024.08.312
Abstrakt:	Objective: To study cycle outcomes of women who choose to pursue oocyte cryopreservation, using published age-specific oocyte recommendations. Design: Retrospective cohort. Setting: Clinic. Patient(s): A total of 5,915 patients seeking planned oocyte cryopreservation, 3,504 ultimately underwent ovarian stimulation with oocyte retrieval and cryopreservation, 425 of this cohort subsequently thawed with intent to use embryo transfer. Exposure: Planned oocyte cryopreservation. Main Outcome Measure(s): Planned oocyte cryopreservation consultation, fertility preservation cycle(s) and ovarian stimulation outcomes. Result(s): A total of 5,915 women were seen in the initial consultation for planned fertility preservation (2012-2022). Ethnicity and the highest level of education were significant in predicting who would move forward with oocyte stimulation for fertility preservation. Women who reported working within the law and public policy and in the fields of health and medicine were statistically more likely to proceed with a cycle than those who listed other occupations. Of 3,504 women in the study cohort who underwent ovarian stimulation and egg retrieval, 1,331 (38.0%) achieved the age-based recommended number of oocytes to freeze. Only 57 (4.3%) of these women who met their age-based oocyte goal did so after their initial cryopreservation cycle. There was a significant association between ethnicity and number of cryopreservation cycles, specifically showing that Black or African American women were less likely to complete two or more cycles. Patients whose education background included graduate or professional degrees were more likely to have completed more than one cycle. Conclusion(s): Self-identified ethnicity was significantly associated with the odds of moving forward with oocyte stimulation for fertility preservation and egg retrieval after initial consultation with ethnic minorities significantly less likely to continue treatment. Of those who undergo egg freezing, most women pursue more than one stimulation and cryopreservation cycle, yet the majority never meet their recommended number to freeze. Competing Interests: Declaration of Interests D.B. has nothing to disclose. M.B. has nothing to disclose. A.C.C. has nothing to disclose. R.Y. has nothing to disclose. S.R. has nothing to disclose. K.D. reports consulting fees from BluDiagnostics and Medscape; honoraria from University of California, San Diego and Pacific Coast Reproductive Society; travel support from The American Society for Reproductive Medicine, The Society for Assisted Reproductive Technology and U.S. Fertility; data safety monitoring boards for Medscape, BluDiagnostics, Future Fertility, and LifeWhisperer; The Society for Reproductive Endocrinology and Infertility Research Chair, The Society for Assisted Reproductive Technology QA Chair, Medical Director; and Chief Research Officer, U.S. Fertility; stocks in U.S. Fertility (indirect) and Shady Grove Fertility; options in LifeWhisperer and Future Fertility. M.H. has nothing to disclose. A.D. has nothing to disclose. T.S. has nothing to disclose. (Published by Elsevier Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu